Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment

[1]  Norbert Schuff,et al.  Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease , 2010, NeuroImage.

[2]  Frederik Barkhof,et al.  Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study , 2010, Neurobiology of Aging.

[3]  Michael Weiner,et al.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection , 2010, NeuroImage.

[4]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[5]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[6]  J. Blass,et al.  Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations , 2010 .

[7]  A. Dale,et al.  Subregional neuroanatomical change as a biomarker for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[8]  Norbert Schuff,et al.  Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects , 2009, NeuroImage.

[9]  Nick C Fox,et al.  Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease , 2009, Neurology.

[10]  J. Cummings.  Defining and labeling disease-modifying treatments for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[11]  Andrew J. Saykin,et al.  Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease , 2009, PloS one.

[12]  Ronald C Petersen,et al.  Early diagnosis of Alzheimer's disease: is MCI too late? , 2009, Current Alzheimer research.

[13]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[14]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[15]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[16]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[17]  M. Davidian,et al.  Covariate adjustment for two‐sample treatment comparisons in randomized clinical trials: A principled yet flexible approach , 2008, Statistics in medicine.

[18]  C. Jack,et al.  Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI , 2008, Neurobiology of Aging.

[19]  Chris Frost,et al.  Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run‐in period increase efficiency? , 2008, Statistics in medicine.

[20]  C. Jack,et al.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype , 2008, Neurology.

[21]  Nick C Fox,et al.  Neuropsychological correlates of whole brain atrophy in Alzheimer's disease , 2008, Neuropsychologia.

[22]  J. Barnes,et al.  A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus , 2008, NeuroImage.

[23]  George F Borm,et al.  A simple sample size formula for analysis of covariance in randomized clinical trials. , 2007, Journal of clinical epidemiology.

[24]  Nick C Fox,et al.  Combining short interval MRI in Alzheimer’s disease , 2006, Journal of Neurology.

[25]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[26]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[27]       .  Global prevalence of dementia: a Delphi consensus study , 2006 .

[28]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[29]  M N Rossor,et al.  Measuring atrophy in Alzheimer disease , 2005, Neurology.

[30]  Alan C. Evans,et al.  Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. , 2005, Archives of neurology.

[31]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[32]  William M. Wells,et al.  Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation , 2004, IEEE Transactions on Medical Imaging.

[33]  Nick C Fox,et al.  Imaging cerebral atrophy: normal ageing to Alzheimer's disease , 2004, The Lancet.

[34]  C. Jack,et al.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD , 2003, Neurology.

[35]  E. Alf,et al.  A New Maximum Likelihood Estimator for the Population Squared Multiple Correlation , 2002 .

[36]  Yudi Pawitan.  Computing empirical likelihood from the bootstrap , 2000 .

[37]  Nick C Fox,et al.  Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. , 1997, Computer methods and programs in biomedicine.

[38]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[39]  Joseph F. Lucke,et al.  The Biases and Mean Squared Errors of Estimators of Multinormal Squared Multiple Correlation , 1984 .

[40]  P. McCullagh,et al.  Some aspects of analysis of covariance. , 1982, Biometrics.